Scarica l'app Stockscreener
6.38
3.33%
-0.22
Pre-mercato:
6.24
-0.14
-2.19%
Precedente Chiudi:
$6.60
Aprire:
$6.56
Volume 24 ore:
1.25M
Relative Volume:
0.94
Capitalizzazione di mercato:
$486.03M
Reddito:
-
Utile/perdita netta:
$-168.09M
Rapporto P/E:
-2.9401
EPS:
-2.17
Flusso di cassa netto:
$-138.01M
1 W Prestazione:
-10.39%
1M Prestazione:
-17.25%
6M Prestazione:
-66.79%
1 anno Prestazione:
-70.76%
Intervallo 1D:
$6.27
$6.58
Intervallo di 1 settimana:
$6.27
$7.31
Portata 52W:
$6.27
$23.48
Kura Oncology Inc Stock (KURA) Company Profile
Nome
Kura Oncology Inc
Settore
Industria
Telefono
(858) 500-8800
Indirizzo
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Confronta KURA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
6.38 | 486.03M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-06 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-14 | Downgrade | Stifel | Buy → Hold |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-08-11 | Iniziato | BofA Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-05-17 | Iniziato | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2022-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Iniziato | Jefferies | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-07 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-11-05 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-11-09 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2016-10-13 | Ripresa | Leerink Partners | Outperform |
| 2016-01-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-12-30 | Iniziato | Oppenheimer | Outperform |
| 2015-12-16 | Iniziato | Citigroup | Buy |
Mostra tutto
Kura Oncology Inc Borsa (KURA) Ultime notizie
Kura Oncology to Participate in Stifel Targeted Oncology Forum - The Manila Times
Kura Oncology CEO Set to Reveal Latest Cancer Treatment Strategy at Elite Stifel Forum - Stock Titan
Kura Oncology stock hits 52-week low at $6.75 amid market challenges - Investing.com
Virtu Financial LLC Makes New Investment in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology (NASDAQ:KURA) Upgraded by StockNews.com to Buy Rating - Defense World
Kura Oncology presents promising preclinical data By Investing.com - Investing.com South Africa
Kura Oncology presents promising preclinical data - Investing.com India
Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting - The Manila Times
Charles Schwab Investment Management Inc. Buys 10,542 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology director Hasnain Faheem sells $181,456 in shares By Investing.com - Investing.com Australia
Insider Sell: Faheem Hasnain Sells 22,682 Shares of Kura Oncology Inc (KURA) - GuruFocus
Kura Oncology director Hasnain Faheem sells $181,456 in shares - Investing.com
Bank of New York Mellon Corp Decreases Stock Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Brokers Issue Forecasts for Kura Oncology FY2025 Earnings - Defense World
Kura Oncology (NASDAQ:KURA) Downgraded by StockNews.com to “Hold” - Defense World
US Bancorp DE Has $193,000 Stake in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
BTIG Research downgrades Kura Oncology Inc (KURA) stock to a Neutral - Knox Daily
Kura Oncology Inc (KURA) Q4 2024 Earnings: EPS of -$0.22 Beats E - GuruFocus.com
Kura Oncology at Leerink Conference: Strategic Advances in AML Therapies By Investing.com - Investing.com UK
Kura Oncology at Leerink Conference: Strategic Advances in AML Therapies - Investing.com
Kura Oncology stock hits 52-week low at $6.98 amid challenges - Investing.com Australia
Kura Oncology stock hits 52-week low at $6.98 amid challenges By Investing.com - Investing.com South Africa
Recent Research Analysts’ Ratings Changes for Kura Oncology (KURA) - Defense World
UBS Group Issues Pessimistic Forecast for Kura Oncology (NASDAQ:KURA) Stock Price - Defense World
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Metrics That Matter About Kura Oncology Inc (NASDAQ: KURA) - Stocks Register
Kura Oncology's Latest Strategic Move: 190K Share Options Package Draws Top Talent - StockTitan
Kura Oncology, Inc. to Host Earnings Call - ACCESS Newswire
Kura Oncology price target lowered to $14 from $27 at UBS - TipRanks
Cantor Fitzgerald Comments on Kura Oncology FY2025 Earnings - Defense World
Kura Oncology (NASDAQ:KURA) Rating Increased to Buy at StockNews.com - Defense World
UBS Adjusts Price Target on Kura Oncology to $14 From $27, Keeps Buy Rating -March 06, 2025 at 09:52 am EST - Marketscreener.com
Kura Oncology’s SWOT analysis: ziftomenib trials key for AML stock’s future - Investing.com India
Kura Oncology’s SWOT analysis: ziftomenib trials key for AML stock’s future By Investing.com - Investing.com South Africa
Kura Oncology (NASDAQ:KURA) Raised to “Strong-Buy” at Cantor Fitzgerald - Defense World
Industry Analysts Just Upgraded Their Kura Oncology, Inc. (NASDAQ:KURA) Revenue Forecasts By 62% - Simply Wall St
Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity - Seeking Alpha
Brokers Issue Forecasts for Kura Oncology FY2026 Earnings - Defense World
What is Wedbush’s Estimate for Kura Oncology Q1 Earnings? - The AM Reporter
FY2025 EPS Estimate for Kura Oncology Reduced by Analyst - Defense World
HC Wainwright Predicts Kura Oncology Q2 Earnings - Defense World
Wedbush Estimates Kura Oncology’s Q1 Earnings (NASDAQ:KURA) - Defense World
Kura Oncology’s (KURA) Outperform Rating Reiterated at Wedbush - Defense World
HC Wainwright Weighs in on Kura Oncology Q1 Earnings - Armenian Reporter
Brokers Offer Predictions for Kura Oncology Q1 Earnings - Armenian Reporter
Kura Oncology’s Financial Future at Risk: Dependency on Kyowa Kirin for Ziftomenib Development Raises Concerns - TipRanks
Research Analysts Set Expectations for Kura Oncology Q1 Earnings - MarketBeat
Equities Analysts Issue Forecasts for Kura Oncology Q1 Earnings - Defense World
Kura Oncology (NASDAQ:KURA) Stock Rating Upgraded by StockNews.com - Defense World
Kura Oncology (NASDAQ:KURA) Upgraded at StockNews.com - MarketBeat
Kura Oncology Inc Azioni (KURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.89%
0.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):